Ressources

Les plus récents rapports, lignes directrices cliniques, publications et présentations ayant utilisé OncoSim sont énumérés ci-dessous. Les ressources dont le titre est en anglais sont disponibles dans cette langue seulement. Afin d’obtenir l’accès aux hypothèses du modèle et aux sources de données, veuillez faire une demande de compte. Pour toute question, envoyez un courriel à oncosim@partenariatcontrelecancer.ca.

Lignes directrices et rapports

Lignes directrices du Groupe d’étude canadien sur les soins de santé préventifs

• Recommendations on screening for colorectal cancer in primary care (mars 2016)
• Recommendations on screening for lung cancer (mars 2016)

Rapports Statistiques canadiennes sur le cancer

• Statistiques canadiennes sur le cancer 2016; Sujet particulier : Les cancers associés au VPH
• Statistiques canadiennes sur le cancer 2015; Sujet particulier : Prévisions concernant le fardeau futur du cancer au Canada

Rapport STE* de l’Alberta, Institute of Health Economics

• Low dose computed tomography for the screening of lung cancer in adults (mai 2014)
  *STE = Analyse démographique Sociale et systémique, effets et efficacité de la Technologie analyse Économique

Publications évaluées par les pairs

Général

• Evans WK, Wolfson MC, Flanagan WM, Shin J, Goffin J, Miller AB, et al. Canadian Cancer Risk Management Model: Evaluation of cancer control. International Journal of Technology Assessment in Health Care. 2013 Apr;29(2):131-9.
• Gauvreau CL, Fitzgerald NR, Memon S, et al. The OncoSim Model: Development and use for better decision-making in Canadian cancer control. Curr Oncol. 2017 Dec; 24 (6); 401-406

Cancer du sein

• Yong JHE, Nadeau C, Flanagan WM et al. The OncoSim-Breast cancer microsimulation model. medRxiv 2020.05.22.20110569

Cancer du col de l’utérus/VPH

• Miller AB, Gribble S, Nadeau C, Asakawa K, Flanagan WM, Wolfson M, et al. Evaluation of the natural history of cancer of the cervix, implications for prevention. The Cancer Risk Management Model (CRMM)—Human papillomavirus and cervical components. Journal of Cancer Policy. 2015 Jun;4:1-6.
• Popadiuk C, Gauvreau CL, Bhavsar M, Nadeau C, Asakawa K, Flanagan WM, et al. Using the Cancer Risk Management Model to evaluate the health and economic impacts of cytology compared with human papillomavirus DNA testing for primary cervical cancer screening in Canada. Curr Oncol. 2016 Feb;23(Suppl 1):S56-S63.
• Lacombe J, Gauvreau CL, Memon S, Popadiuk C, Flanagan WM, Nadeau C, et al. Exploring the health outcomes of various pan-Canadian cervical cancer screening programs using microsimulation modeling. Am J Epidemiol. 2016;184(1):78-80.
• Popadiuk C, Coldman A, Memon S, et al. Comparing the health and economic impacts of cervical cancer screening strategies using the Cancer Risk Management Model (CRMM). Gynecologic Oncology 2016; (141): 63.
• Popadiuk C, Decker K, Gauvreau C. Starting cervical cancer screening at 25 years of age: the time has come. CMAJ. 2019 Jan; 191 (1)
• Smith A, Baines N, Memon S et. Al. Moving towards the elimination of cervical cancer: modeling the health and economic benefits of increasing HPV vaccine uptake. Curr Oncol. 2019;26(2):80–84.

Cancer colorectal

• Coldman AJ, Phillips N, Brisson J, Flanagan W, Wolfson M, Nadeau C, et al. Using the Cancer Risk Management Model to evaluate colorectal cancer screening options for Canada. Curr Oncol. 2015 Apr;22(2):e41-50.
• Coldman AJ, Flanagan WM, Nadeau C et al. Projected Effect of Fecal Immunochemical Test Threshold for Colorectal Cancer Screening on Outcomes and Costs for Canada using the OncoSim Microsimulation Model. J Cancer Policy. 2017 Sept; 13: 38-46
• Coldman AJ, Pader J, Gauvreau, C, et al. Simulating Results from Trials of Sigmoidoscopy Screening Using the OncoSim Microsimulation Model. J Cancer Policy. 2018 Mar; 15: 52-58

Cancer du poumon

• Evans WK, Wolfson M, Flanagan WM, Shin J, Goffin JR, Asakawa K, et al. The evaluation of cancer control interventions in lung cancer using the Canadian Cancer Risk Management Model. Lung Cancer Manage. 2012 June;1(1):25-33.
• Louie AV, Rodrigues GB, Palma DA, Senan S. Measuring the population impact of introducing stereotactic ablative radiotherapy for stage I non-small cell lung cancer in Canada. Oncologist. 2014 Aug;19(8):880-5.
• Fitzgerald NR, Flanagan WM, Evans WK, Miller AB. Eligibility for low-dose computerized tomography screening among asbestos-exposed individuals. Scand J Work Environ Health. 2015 Jul;41(4):407-12.
• Flanagan WM, Evans WK, Fitzgerald NR, Goffin JR, Miller AB, Wolfson MC. Performance of the cancer risk management model lung cancer screening module. Health Rep. 2015 May;26(5):11-8.
• Goffin JR, Flanagan WM, Miller AB, Fitzgerald NR, Memon S, Wolfson MC.Cost-effectiveness of lung cancer screening in Canada. JAMA Oncol. 2015 Sep;1(6):807-13.
• Evans WK, Flanagan WM, Miller AB, Goffin JR, Memon S, Fitzgerald N, et al. Implementing low-dose computer tomography screening for lung cancer in Canada: implications of alternative at-risk populations, screening frequency and duration. Curr Oncol. 2016 Jun;23(3):e179-87.
• Goffin JR, Flanagan WM, Miller AB, Fitzgerald NR, Memon S, Wolfson MC, et al. Biennial lung cancer screening in Canada with smoking cessation—outcomes and cost-effectiveness. Lung Cancer. 2016 Nov;101:98-103.
• Evans WK, Gauvreau C, Flanagan WM et al. Estimating the cost effectiveness and clinical impact of adding smoking cessation to an organized CT lung cancer screening program in Canada. CMAJ Open, 8(3), E585–E592.

Affiches

• Translating research to inform policy decisions. 2019.
• The OncoSim-Breast model reproduces the observed effects of a randomized screening trial. 2019.
• Family history-based colorectal cancer screening. 2019.
• The cost of failed first-line cancer treatment due to smoking in Canada. 2019.
• Potential benefits of reducing breast cancer screening abnormal call rates. 2019.
• Cancer burden attributable to risk factors. 2019.
• Costs and cost-effectiveness of smoking cessation within an organized CT lung cancer screening program. 2018.
• How in the real world are lung cancer patients treated? 2018.
• Lung cancer-related clinical and economic impacts of achieving a 5% smoking rate by 2035 in Canada. 2018.
• Comparing the health and economic outcomes of opportunistic lung cancer screening vs. organized lung screening using the Cancer Risk Management Model. 2016.
• Annual vs. biennial lung cancer screening using the Cancer Risk Management Model to fill gaps in evidence. 2014.
• Comparing the health and economic impacts of two screening strategies for colorectal cancer in Canada using the Cancer Risk Management Model (CRMM). 2014.

Multimédia

• Infographie : Causes of cervical cancer: HPV 16 & 18.

Formation

Pour apprendre à utiliser la plateforme OncoSim, téléchargez le guide de l’utilisateur d’OncoSim (en anglais). Cette ressource pratique fournit des renseignements détaillés sur les sous-modèles, ainsi que des exemples d’applications. Vous découvrirez comment comprendre, analyser, modifier et réaliser divers scénarios et simulations.

Documentation sur le modèle

Pour consulter d’autre documentation sur le modèle, tels que le dictionnaire de données, les hypothèses sur le modèle et l’information sur la structure du modèle, veuillez faire une demande de compte.